Loading...

ENTO ENTERO THERAPEUTICS INC Company Mergers 8-K Filing

NTR

NT

ENTERO THERAPEUTICS INC

(ENTO)

FY2023 8 K

NTR

NT

ENTERO THERAPEUTICS INC

(ENTO)

FY2023 8 K

Filing:

8 K

Published on:

10 Oct '23

Debt Restructuring

Nasdaq Compliance

Merger Rescission

Management Changes

Nasdaq Compliance Notice

Debt Default Notice

Acquisition Agreement

Nasdaq Compliance Notice

Licensing Agreement

Auditor Resignation

Acquisition and Default on ...

Resignation of Chief Scient...

Warrant Exercise Inducement...

Management Change

Change in Independent Accou...

Merger of Equals

Registered Direct Offering

Amendment to Form 8-K

Earnings Reports

Acquisition of ImmunogenX, ...

Registered Direct Offering

Regulation FD Disclosure

Warrant Exercise Inducement...

Sale of Niclosamide Program

Acquisition of ImmunogenX, ...

Reverse Stock Split

Delisting Notice

Amendment to License Agreement

Warrant Exercise Inducement...

License Agreement with Sanofi

Annual Meeting of Stockholders

Warrant Exercise Inducement...

Retention Bonuses and Annua...

Shareholder Director Nomina...

Private Placement Offering

Nasdaq Compliance

External Links:

AI Assistant

ENTERO THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.